https://www.selleckchem.com/pr....oducts/chk2-inhibito
Lumasiran reduces urinary and plasma oxalate (POx) in patients with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function. ILLUMINATE-C evaluates the efficacy, safety, pharmacokinetics, and pharmacodynamics of lumasiran in patients with PH1 and advanced kidney disease. Phase 3, open-label, single-arm trial. Multinational study; enrolled patients with PH1 of all ages, estimated glomerular filtration rate≤45 mL/min/1.73 m (if age≥12 months) or increased serum creatinine level (if age12 months), a
Like
Comment
Share
